Jaguar Health, Inc. (JAGX): Nasdaq/NYSE listing notice — Jaguar Health receives Nasdaq delisting notice for bid price; plans to appeal

Jaguar Health, Inc.

Nasdaq notice on March 5, 2026: bid price below $1.00 for 30 consecutive business days.
Company ineligible for compliance period due to reverse stock split(s) in prior two years.
Must request appeal by March 12, 2026; intent to timely appeal to Hearings Panel.
Appeal request automatically stays suspension pending hearing outcome; no guarantee of relisting.
Ticker JAGX trades on Nasdaq; delisting would occur if appeal fails.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Jaguar Health, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)(iv)

Exact text from the filing

March 5, 2026, Jaguar Health, Inc. (the “Company”) received a written notification (the “Notice”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that because the bid price for the Company’s common stock for the previous 30 consecutive business days had closed below the minimum $1.00 per share, the Company was no longer in compliance with the requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). Further, the Notice stated that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)

View on SEC.gov

2 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-096565

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.